Who Should Not Take Semaglutide? Contraindications and Red Flags

Most of the conversation around semaglutide focuses on what it can do: suppress appetite, promote meaningful weight loss, improve metabolic health markers. And that conversation is valid — the evidence is strong.

But there is an equally important conversation that does not get enough attention: who should not take semaglutide.

Every prescription medication has contraindications — medical conditions, histories, or circumstances where the medicine could cause more harm than benefit. Semaglutide is no exception. It is a potent drug that affects hormones, digestion, blood sugar, and multiple organ systems. For the right patient, it is transformative. For the wrong patient, it could be dangerous.

This article is not meant to scare you. It is meant to inform you — honestly and completely — so that you walk into a medical consultation already understanding why your doctor will ask certain questions and why some patients are told this medicine is not suitable for them.

If you recognise any of the conditions below in your own health history, that does not automatically mean you cannot use semaglutide. It means you need a careful, honest conversation with your clinician before any prescription is written.

Let us start with the clearest category: situations where semaglutide is contraindicated, meaning the prescribing label explicitly states it should not be used.

Personal or Family History of Medullary Thyroid Carcinoma (MTC)

This is the most prominent boxed warning on semaglutide's prescribing information. In preclinical studies conducted on rodents, semaglutide and other GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumours, including medullary thyroid carcinoma.

While this specific effect has not been confirmed in humans, the risk cannot be ruled out. As a precaution, semaglutide is contraindicated in anyone with:

• A personal history of medullary thyroid carcinoma
• A family history of MTC in a first-degree relative (parent, sibling, or child)

If you have ever been diagnosed with MTC or if this cancer runs in your family, you must disclose this to your doctor before considering semaglutide or any GLP-1 receptor agonist.

Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2)

MEN 2 is a rare inherited genetic condition that significantly increases the risk of developing medullary thyroid carcinoma and tumours of other endocrine glands. Patients with MEN 2 should not use semaglutide under any circumstances.

Known Hypersensitivity to Semaglutide

If you have previously had an allergic reaction to semaglutide or any of the inactive ingredients in its formulation, the medication is contraindicated. Signs of a serious allergic reaction include facial swelling, difficulty breathing, severe rash, or anaphylaxis. Though rare, this possibility exists with any injectable medication.

Pancreatitis — inflammation of the pancreas — is one of the most closely watched safety signals with GLP-1 receptor agonists, including semaglutide.

In clinical trials, cases of acute pancreatitis were reported in patients taking semaglutide, though the overall incidence was low. The prescribing information advises that semaglutide should be used with caution in patients with a history of pancreatitis, and some clinicians may consider it a relative contraindication depending on the severity and recency of prior episodes.

What Pancreatitis Feels Like

The hallmark symptom is severe, persistent abdominal pain — often in the upper abdomen, sometimes radiating to the back. It may be accompanied by nausea, vomiting, fever, and a rapid pulse. This is not the same as mild stomach discomfort or bloating. Pancreatitis pain is typically intense and does not resolve on its own.

What Your Doctor Will Consider

If you have a history of pancreatitis, your clinician will evaluate:

• How recently the episode occurred
• Whether the cause was identified and resolved (for example, gallstones or heavy alcohol use)
• Whether you have ongoing risk factors for recurrence
• Whether the potential benefits of semaglutide outweigh the risks in your specific case

If semaglutide is prescribed despite a pancreatitis history, closer monitoring will be necessary. And if you develop symptoms suggestive of pancreatitis while on treatment, the medication should be stopped immediately and you should seek emergency medical care.

Rapid weight loss — regardless of how it is achieved — increases the risk of developing gallstones (cholelithiasis). Since semaglutide can produce significant weight loss, this risk is clinically relevant.

In the STEP clinical trials, gallbladder-related events (including gallstones, gallbladder inflammation, and the need for surgical removal of the gallbladder) occurred at a higher rate in semaglutide-treated patients compared to those on placebo.

Who Needs Extra Caution

• Patients with a prior history of gallstones or gallbladder disease
• Patients who have had their gallbladder removed (cholecystectomy) — while this eliminates the risk of new gallstones, bile duct complications can still occur
• Patients with known bile duct abnormalities

Symptoms to Watch For

Gallbladder problems typically present as:

• Sudden, intense pain in the upper right abdomen, often after eating
• Pain that radiates to the right shoulder or between the shoulder blades
• Nausea and vomiting
• Fever or chills (suggesting infection or inflammation)
• Jaundice — yellowing of the skin or the whites of the eyes

If you experience these symptoms while on semaglutide, contact your clinician promptly. Gallbladder issues are treatable, but they require medical attention and should not be dismissed as routine side effects.

Semaglutide's most common side effects are gastrointestinal — nausea, vomiting, and diarrhoea, particularly during dose escalation. For most patients, these symptoms are manageable. But for patients with pre-existing kidney disease, they carry additional risk.

Vomiting and diarrhoea can cause significant fluid loss, leading to dehydration. Dehydration, in turn, reduces blood flow to the kidneys and can cause acute kidney injury — a sudden decline in kidney function. In patients whose kidneys are already compromised, this can be particularly dangerous.

Post-Marketing Reports

Since semaglutide entered widespread use, there have been post-marketing reports of acute kidney injury and worsening of chronic kidney disease in patients taking GLP-1 receptor agonists. Many of these cases were associated with dehydration from gastrointestinal side effects.

What This Means for You

If you have chronic kidney disease, even at a mild stage, your clinician needs to know before prescribing semaglutide. Additional precautions may include:

• More frequent monitoring of kidney function through blood tests (creatinine, eGFR)
• Lower starting doses and slower titration
• Clear instructions on hydration and when to seek help if you cannot keep fluids down
• In some cases, a decision that the risks outweigh the benefits

Patients on semaglutide should also be aware that adequate hydration is not optional. If you are vomiting repeatedly or have persistent diarrhoea and cannot maintain fluid intake, contact your clinician immediately — do not wait for your next scheduled appointment.

Semaglutide is not recommended during pregnancy. Animal studies have shown adverse effects on foetal development, and there is insufficient data on semaglutide use in pregnant humans to establish safety. The prescribing information is clear: semaglutide should be discontinued if pregnancy is detected.

Planning to Conceive

Current guidance recommends stopping semaglutide at least two months before a planned pregnancy. This washout period accounts for the drug's long half-life, ensuring it is substantially cleared from your system before conception.

This is an important consideration for women of reproductive age. If you are thinking about becoming pregnant in the near future, discuss this with your clinician before starting semaglutide. Starting a medication only to stop it weeks later is not ideal for your body or your treatment plan.

Breastfeeding

There is limited data on whether semaglutide passes into breast milk or what effect it might have on a nursing infant. As a precaution, semaglutide is generally not recommended during breastfeeding. Your clinician will weigh the benefits of treatment against potential risks to your child.

A Note on Fertility

There is emerging discussion about whether GLP-1 medications may improve fertility in women with conditions like polycystic ovary syndrome (PCOS) by improving metabolic health and promoting weight loss. While this is an active area of research, it also means that unplanned pregnancies may be more likely after starting treatment. Reliable contraception should be discussed with your clinician if you are of childbearing age and not planning a pregnancy.

Because semaglutide fundamentally affects how your digestive system operates — slowing gastric emptying, altering appetite, and changing stool patterns — patients with certain pre-existing gastrointestinal conditions need careful evaluation.

Gastroparesis

Gastroparesis is a condition where the stomach empties abnormally slowly even without any mechanical obstruction. Since semaglutide further slows gastric emptying, it can worsen symptoms in patients with gastroparesis — potentially causing severe nausea, vomiting, bloating, and abdominal pain. Most clinicians consider gastroparesis a relative contraindication to GLP-1 therapy.

Inflammatory Bowel Disease (IBD)

Patients with Crohn's disease or ulcerative colitis may experience unpredictable interactions between their underlying condition and the gastrointestinal effects of semaglutide. While GLP-1 medications are not specifically contraindicated in IBD, the potential for overlapping GI symptoms complicates monitoring and management. A gastroenterologist should be involved in the decision.

History of Bowel Obstruction

Patients with a history of bowel obstruction or conditions that predispose to it (such as extensive abdominal adhesions from prior surgery) should use GLP-1 medications with caution. Slowed gut motility in the context of an already-compromised bowel can create dangerous complications.

The Broader Point

If you have any chronic gastrointestinal condition — even one not listed here — make sure your prescribing clinician is fully aware. The GI tract is where semaglutide exerts many of its primary effects, so any pre-existing abnormality in that system is clinically relevant.

This section is not about a medical condition. It is about a dangerous trend that puts patients at risk.

As demand for semaglutide has surged globally, so has the availability of compounded semaglutide — products made by compounding pharmacies rather than by the original manufacturer (Novo Nordisk). In some cases, these products are sold online without a valid prescription, without proper medical evaluation, and without any guarantee of safety, sterility, or correct dosing.

Why This Matters

• Compounded products are not equivalent to approved medications. They have not undergone the same rigorous testing, manufacturing quality controls, or regulatory review as branded semaglutide (Ozempic, Wegovy, Rybelsus).
• Dosing may be inaccurate. Compounded formulations may contain more or less active ingredient than labelled, which can lead to ineffective treatment or dangerous overdose.
• Contamination risks exist. Without pharmaceutical-grade manufacturing standards, compounded products may carry risks of bacterial contamination, incorrect pH, or presence of impurities.
• No medical oversight. Products sold without a prescription bypass the critical step of clinical evaluation — meaning patients with contraindications may unknowingly put themselves at serious risk.

Regulatory Warnings

The US FDA has issued safety communications warning about the risks of compounded semaglutide products. In India, the DCGI (Drug Controller General of India) regulates which medications can be legally manufactured and sold. Purchasing medications from unverified online sources or overseas pharmacies that bypass Indian regulatory approval is both illegal and medically risky.

The bottom line: if you cannot verify that your semaglutide comes from a licensed, regulated source and was prescribed after a proper medical evaluation, do not use it.

Everything in this article leads to one critical point: semaglutide is not a medicine you should start on your own.

We understand the temptation. The results are compelling. Friends or family members may be having success with it. Online pharmacies make it seem as easy as ordering a package. But the risks of self-prescribing are real and serious:

• You may have a contraindication you do not know about. Many of the conditions listed in this article — like a family history of MTC or early-stage kidney disease — may not cause symptoms. Only a proper medical evaluation with blood work can identify them.
• Dosing requires supervision. Semaglutide must be titrated gradually over weeks. Starting at the wrong dose, escalating too fast, or using a dose meant for someone else can cause severe GI symptoms, dehydration, and metabolic disturbance.
• Drug interactions matter. Semaglutide slows gastric emptying, which can affect the absorption of other oral medications you take — including blood pressure pills, oral contraceptives, and diabetes drugs. A doctor needs to review your full medication list.
• Monitoring is part of the treatment. Blood sugar levels, kidney function, thyroid health, and gallbladder status should be monitored during treatment. Without this monitoring, problems can develop silently until they become emergencies.

Self-prescribing semaglutide is not a shortcut. It is a gamble with your health — one where the stakes include pancreatitis, kidney damage, severe allergic reactions, and undiagnosed thyroid disease.

If you have read this article and you are wondering whether semaglutide is safe for you specifically, the answer is straightforward: ask a doctor.

Not a friend. Not a forum. Not a social media influencer. A licensed clinician who will:

• Take a thorough medical history, including conditions that may not seem related to weight
• Review your family history for thyroid cancer and other hereditary conditions
• Order appropriate blood work — thyroid function, kidney function, pancreatic enzymes, blood sugar markers, and lipid profile
• Review all your current medications for potential interactions
• Discuss pregnancy plans if relevant
• Explain the risks and benefits honestly, so you can make an informed decision

At Zelta, this is exactly what our consultations are designed to do. Our clinicians are experienced in prescribing GLP-1 medications and understand the complete picture — not just the weight-loss potential, but the safety considerations that must come first.

Book a specialist consultation at zelta.in. Find out whether semaglutide is safe and appropriate for your individual health — before you take a single dose. A one-time consultation fee applies. If you proceed with a treatment plan, the amount paid is adjusted against the plan price.

This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. The contraindications and cautions discussed are based on current prescribing information and published clinical evidence, but they do not represent an exhaustive list. Individual risk assessment requires a thorough medical evaluation by a qualified clinician. Never start, stop, or change a medication without consulting your doctor. If you are experiencing symptoms of a medical emergency — including severe abdominal pain, difficulty breathing, swelling of the face or throat, or signs of a severe allergic reaction — seek emergency medical care immediately. Drug availability and approved indications in India are subject to CDSCO regulations and may differ from international approvals.